SELECT EXAMPLES S AA 02530132 S AC "GENERAL HOSPITAL AND PERSONAL USE"? S CO ULSTER SCIENTIFIC? S DN K864761 S DT DEVICE S EQ SE D1411365-2000-00009 S LA ENGLISH S LT SHORT S LT LONG S ME ANTIGEN W ; REACTION ; S ME U-304 ; ? S NA METOCLOPRAMIDE TABLET? S PD 20041130 S PE 20051018? S PN US 4410520 S PY 2004 S RT FULLTEXT S SD 19861205 S SO FDA W ; ENFORCEMENT W ; REPORT ; S TN LOTREL S UD 9999 S WD 143. Health care professionals, law enforcement personnel, and regulators all share a responsibility for ensuring that prescription-pain medications are available to the patients who need them, and for preventing these drugs from being misappropriated or misused. All stakeholders must ensure that accurate information about both the legitimate use and the abuse of opioids is made available, and efforts are ongoing in this regard on several fronts. Nonetheless, the fact remains that chronic noncancer pain is widely undertreated, and it is likely that heightened scrutiny of physicians and sanctions for inappropriate prescribing will have an adverse effect on patient care. In considering the use of opioids in pain management, currently the best guide for physicians is sound clinical judgment based on the patient's specific pain condition and any comorbid disorders. Formal policies, for example, lotrel package insert. 3 Hill, C. E., Phillips, J. K. and Sandow, S. L. 2001 ; Heterogeneous control of blood flow amongst different vascular beds. Med. Res. Rev. 21, 160 4 Franowicz, J. S., Kessler, L. E., Borja, C. M., Kobilka, B. K., Limbird, L. E. and Arnsten, A. F. 2002 ; Mutation of the 2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 22, 87718777 5 Avery, R. A., Franowicz, J. S., Studholme, C., van Dyck, C. H. and Arnsten, A. F. 2000 ; The 2A -adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 23, 240249 6 Scahill, L., Barloon, L. and Farkas, L. 1999 ; 2 Agonists in the treatment of attention deficit hyperactivity disorder. J. Child Adolesc. Psychiatry Nurs. 12, 168173 7 Tavares, A., Handy, D. E., Bogdanova, N. N., Rosene, D. L. and Gavras, H. 1996 ; Localization of 2A - and 2B -adrenergic receptor subtypes in brain. Hypertension 27, 449455 8 Altman, J. D., Trendelenburg, A. U., MacMillan, L. et al. 1999 ; Abnormal regulation of the sympathetic nervous system in 2A -adrenergic receptor knockout mice. Mol. Pharmacol. 56, 154161 9 Hein, L., Altman, J. D. and Kobilka, B. K. 1999 ; Two functionally distinct 2 -adrenergic receptors regulate sympathetic neurotransmission. Nature London ; 402, 181184 10 Makaritsis, K. P., Johns, C., Gavras, I. and Gavras, H. 2000 ; Role of 2 -adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension 35, 609613.

And whether the economic resources exist to pay the Take-away Points higher copayment that accompanies a higher tier 19 reported Insurance plans are inconsistent in their coverage of the most commonly placement. The Kaiser Family Foundation dispensed drugs. Patients should examine each plan on a case-by-case in 2005 that the mean copayment was $22 for tier-2 basis to determine which is most beneficial to their health needs. drugs and $35 for tier-3 drugs. These findings are I Across 12 insurance plans, 67 commonly prescribed brand-name drugs were rated as having preferred placement 59.1% of the time. consistent with the mean copayments of $21 and I Patients need to determine whether and to what extent a particular $36 for tier-2 and tier -3 drugs, respectively, as given drug is covered. They may need to weigh the direct health benefits of in Table 1. A difference of $13 to $15 per copayment selecting a plan that offers a 3-tier formulary that covers only a certain percentage of drugs, compared with another plan that covers a broader between tier-2 and tier-3 drugs may be insignificant range of medications. for some patients but may be large enough to deter other patients from using tier-3 drugs, especially if they must take the medication for the rest of their lives. At least in the short run, patients might be well advised to determine whether and to what extent a particular expressing formulary limitations. While the more restrictive drug is covered. For example, breadth of formulary coverage Medicaid plan was specific and outlined all of the formulary may not be as important as the level of coverage for a narrow limitations directly on the publicly available formulary, the group of drugs the patient may already be taking. While not other Medicaid plan simply stated whether each drug was forthe focus of this investigation, patients from a clinical stand- mulary or nonformulary ie, the latter plan did not specify point may need to weigh the direct health benefits of select- when prior authorization or step therapy restrictions existed ; . ing a plan that offers a 3-tier formulary that covers only a Therefore, it may seem that one Medicaid plan is far more certain percentage of drugs, compared with another plan that comprehensive than the other, when in reality it may just communicate its restrictions less effectively. covers a much broader range of medications. The drug classes most represented in our study were the It seems reasonable to assume that the list of the most widely prescribed medications would serve as a good proxy for cardiovascular agents. For this reason, we chose to create a the most clinically relevant treatments. However, prescribing cardiovascular index for the cardiovascular agents in the top patterns are affected by pharmaceutical manufacturers' physi- 67 patented brand-name drugs. The 16 drugs that qualified for cian detailing and by marketing and promotional activities to the cardiovascular index had mean preferred placement index practitioners and patients. Therefore, the list of drugs exam- ratings that were similar to those of the preferred placement ined in our analysis may not reflect the most essential drugs index. Therefore, the cardiovascular agents included in the for individual patients or for populations of enrollees. top 67 brand-name patented drugs do not exhibit a trend that Furthermore, some may argue that it is only necessary to have is any different from that of the primary analysis. Insurers did at least 1 drug on tier 2 within a therapeutic class and that it not treat this class of drugs any differently than the other drugs may be unnecessary to have any tier-2 drug if an over-the- on their formulary. The range of coverage of the cardiovascucounter alternative is available. There are some obvious prob- lar drugs was almost as large as the range in preferred placelems with this for enrollees who switch insurance plans and ment of all 67 patented brand-name drugs in the study. may feel pressured to change drugs. Furthermore, the efficacy Clearly, there were some cardiovascular agents such as Diovan and safety profiles of drugs for individual patients, especially and Lotrwl that were covered by most insurers, but there were those with complex diseases or those using polypharmacy, also some cardiovascular agents such as Crestor and Benicar that were covered on tier 2 by few insurers. limit a "1 size fits all" approach. The insurer's decision regarding tier placement of new There were some drugs that received generally good coverage across all plans. Fosamax, Flonase, Lantus, Advair Diskus, drugs is related to whether the insurer perceives any therapeuCoreg, Diovan, Evista, Lotrel, Valtrex, and Zithromax were tic advantage of the new drug, compared with existing therathe drugs covered most extensively by the sample of insurers pies in the marketplace. This raises the issue of whether it is we examined. Furthermore, of 12 plans examined, the 2 necessary to have a formulary that covers all drugs. A high Medicaid programs were at the low and high ends of the cov- percentage of coverage does not necessarily imply a high-qualerage spectrum of the top 67 brand-name drugs still on patent. ity formulary, because the ideal formulary would include the For instance, one Medicaid plan covered 79.1%, with the most cost-effective drugs within each class and would exclude other plan covering only 35.8% of the top 67 drugs on pre- those that are deemed less beneficial in health and monetary ferred placement. However, the plans were inconsistent in aspects. For this study, we looked at only 1 formulary per plan and lysergic.

Drug Name lindane shampoo LIPITOR TABLET lipram-cr5 capsule dr lisinopril tablet lisinopril hydrochlorothiazide tablet lithium carbonate capsule lithium carbonate tablet lithium carbonate tablet sa lithium citrate solution LITHOBID TABLET SA loestrin 24 fe tablet loperamide hcl capsule LOPRESSOR AMPUL LORABID CAPSULE LORABID SUSP RECON LOTREL CAPSULE LOTRONEX TABLET lovastatin tablet LOVENOX SYRINGE LOVENOX VIAL loxapine succinate capsule LUFYLLIN TABLET LUFYLLIN-400 TABLET LUMIGAN DROPS LUNESTA TABLET LUPRON DEPOT KIT LUPRON DEPOT KIT LUPRON DEPOT SYRINGE LUPRON DEPOT-PED KIT LUPRON KIT LUPRON VIAL LUSONEX PLUS TAB.SR 12H LYRICA CAPSULE LYSODREN TABLET MAGNESIUM SULFATE IN DEXTROSE INFUS. BTL MAGNESIUM SULFATE INFUS. BTL and macrobid.

Online Pharmacy Table 1: Guidelines for storage life of meat during shipment 6 ; . Vacuum pack 0C Pork Lamb Beef 6 weeks 7 weeks 10 weeks Vacuum pack -1.5C 8 weeks 10 weeks 14 weeks CO2 -1.5C 12 weeks. 7.23 What results can we expect from modern weight-loss drugs? and medroxyprogesterone. Non-adrenergic imidazoline binding sites were recently reported to be pharmacologically distinct from 2-adrenoceptors. These sites were studied and identified in several tissues, including rabbit kidney cells Coupry et al., 1987, 1989 ; , pig kidney Vigne et al., 1989 ; , fat cells Langin and Lafontan, 1989 ; , rat liver and lung, human platelets Zonnenschein et al.

Lotrel on line When two is not better than one from a practical perspective, the biggest problem with the traditional approach was the need for multiple medications, raising spectres of patient compliance and expense and mescaline. LOTEMAX LOTREL lovastatin * LOVENOX LUMIGAN LUNESTA LUPRON LUPRON DEPOT LYRICA MAVIK MAXAIR AUTOHALER MAXALT MAXALT MLT MAXAQUIN medroxyprogesterone acetate * megestrol acetate * MENEST MENOSTAR MENTAX meperidine hcl * mercaptopurine * MERIDIA METADATE CD M ; METADATE ER M ; METAGLIP METANX metformin hcl * , er * methamphetamine hcl methimazole * methotrexate * methyldopa * methylin, -er * methylphenidate er * methylphenidate hcl * methylprednisolone * metoclopramide hcl * metolazone * metoprolol tartrate * METROGEL METROLOTION metronidazole 0.75% ; * metronidazole * MIACALCIN M ; MICARDIS MICARDIS HCT microgestin fe * minocycline hcl * MIRAPEX MIRCETTE M ; mirtazapine * misoprostol * MOBIC MODICON mometasone furoate * mononessa * morphine sulfate, -er * MS CONTIN MSIR mupirocin * MYFORTIC. Society, colorectal cancer accounts for the third-most common cancer in men and women in the United States and affects nearly 130, 000 new cases per year. The majority of colorectal cancers are adenocarcinomas, most of which arise from adenomatous polyps. At diagnosis, roughly 30% of patients have metastatic disease. The recommended dose of Avastin is 5 mg kg given once every 14 days as an IV infusion until disease progression is detected. Avastin infusions should not be administered or mixed with dextrose solutions. AVASTIN SHOULD NOT BE ADMINISTERED AS AN IV PUSH OR BOLUS. The drug is supplied as single-unit 100 mg or 400 mg vials. The most serious adverse events associated with Avastin were: gastro and methamphetamine.

Drug Name1 Advair Diskus Allegra-12h Ambien Celebrex Diovan Effexor XR Flonase Fosamax Glucophage Levaquin Lipitor Loyrel Neurontin Nexium Nolvadex Norvasc Ortho Tri-Cyclen Plavix Premarin Prevacid Risperdal Singulair Synthroid Toprol XL Viagra Zithromax Z-pak Zocor Zoloft Zyprexa Zyrtec Gabapentin Levoxyl Lovastatin Metformin Tamoxifen Trinessa Ohio Cash Price2 $174.90 $51.32 $99.48 $208.15 $171.13 $339.90 $79.14 $82.43 $92.44 $108.99 $230.09 $234.66 $65.19 $142.41 $377.74 $221.15 $124.61 $124.02 $102.03 $140.72 $223.41 $101.10 $48.62 $45.38 $200.18 $49.72 $247.01 $283.70 $1, 128.08 $70.37 $63.00 $15.05 $46.55 $16.97 $170.95 $86.39 Ohio's Best MailOrder3 $194.90 $37.37 $87.23 $141.86 $112.39 $263.74 $56.06 $62.24 $70.07 $72.76 $173.53 $182.97 $56.67 $100.76 $313.85 $169.18 $102.69 $102.58 $79.93 $110.76 $165.27 $72.94 $44.75 $30.17 $238.20 $37.15 $192.95 $214.43 $897.33 $49.93 $27.36 $5.50 $23.13 $4.40 $114.43 $52.90 Maine Cash Price $187.34 $52.05 $118.65 $206.19 $165.29 $358.42 $90.16 $91.37 $86.41 $119.19 $261.20 $267.85 $71.46 $152.88 $432.79 $243.95 $141.79 $143.37 $130.32 $158.64 $250.99 $112.06 $46.26 $51.33 $303.14 $59.32 $300.32 $311.47 $1, 321.87 $88.46 $56.56 $18.19 $47.93 $16.75 $213.71 $108.86 Maine Rx Price Mail-Order $140.24 $38.30 $85.87 $160.48 $118.88 $285.00 $64.45 $69.87 $72.52 $82.73 $198.36 $197.91 $50.69 $115.12 $322.55 $191.41 $105.98 $105.86 $94.15 $120.05 $188.43 $83.50 $43.21 $34.90 $268.95 $42.51 $205.84 $242.36 $921.00 $56.42 $22.30 $5.70 $17.15 $9.44 $139.37 $48.98.
A 25-yr-old male with a history of poorly controlled asthma collapsed at home in the late afternoon, having complained of shortness of breath since the day before. The collapse was witnessed by his father, but it was unlikely that effective cardiopulmonary resuscitation CPR ; had been carried out before the arrival of the ambulance crew. When the paramedics arrived, 6 min after the emergency services had been contacted, there was no respiratory effort and no palpable pulse. The ECG monitor showed a heart rate of 24 beats min1. CPR was commenced and the patient's trachea was intubated. After a further 3 min, the carotid pulse became palpable, increasing to a rate of 107 beats min1. The patient started to breathe but remained unconscious, with a Glasgow coma score GCS ; of 3. An oxygen saturation of 98% was achieved at the scene with assisted ventilation and the patient was transferred to the accident and emergency department. On admission to the accident and emergency department, the patient was making spontaneous respiratory effort and his oxygen saturation was 100%. The heart rate was 120 beats min1, with an arterial pressure of 190 120 mm Hg. The pupils were dilated but reactive to light. The patient was initially unresponsive, and within 5 min he and methylphenidate. BIOCINE TEST PPD BIODRAMINA BIODRAMINA BIODRAMINA INFANTILE BIOELECTRA CALCIUM 500 BIOFERON 1 M.I.U BIOFERON 10 M.I.U. BIOFERON 3 M.I.U BIOFERON 5 M.I.U BIOFLOR BIOFLOR BIOLECTRA CALCIUM 500 BIOPLUS EFFERVESCENT TABLETS, because generic name for lotrel. To touch, hairless, thin, and brittle, with a shiny texture. The toenails thicken and become opaque and may be lost. Gangrene of the extremities may also occur. Examination of the arterial system may show a decreased or absent pulse in the dorsalis pedis and posterior tibial arteries. There may be bruits in the proximal leg arteries, indicating the presence of atherosclerosis. Patients with arterial ulcers have a reduced capillary refill time. With normal capillary refill, after compression of the great toe or dorsum of the foot for a few seconds, the skin colour should return to normal in less than two to three seconds. Delay in return of the normal colour is indicative of vascular compromise. A delay of more than 10 to 15 seconds in return of colour after raising an ischaemic leg to 45 degrees for one minute Buerger's test ; indicates vascular compromise. The ankle brachial pressure index is helpful in identifying peripheral vascular disease in the absence of non-compressible vessels resulting from vessel calcification for example, diabetes ; or tissue oedema. A duplex ultrasound scan will give further information--on arterial occlusion, stenosis, and areas of diffuse and continuous atheromatous disease. Arteriography is the ideal investigation in preoperative planning, allowing direct assessment of the vascular anatomy of the lower limb and methylprednisolone. Department of Obstetrics and Gynaecology, Imperial College School of Medicine at St. Mary's, London W2 1PG, UK.

Contd from page 1 cited alarming new statistics; around 13 percent of us were socially phobic . Enter the socially anxious celebrities . last month, the New Orleans Saints running back Ricky Williams told reporters that his social anxiety disorder had been officially diagnosed and that he is now medicated for it. The syndrome, he said, accounted for his unusual behaviour: keeping his helmet on during rookie-year interviews, curling up inside his locker."8 There has also been disquiet about the involvement of the pharmaceutical industry with journalists, including sponsorship to attend conferences and then write articles about specific diseases or conditions. As one experienced health journalist said: "I have taken company sponsored trips. and entered health journalism awards. But no more. With compelling evidence to show that close ties with industry can influence doctors' behaviour, there's no reason to expect journalists would be any different."9 Audrey Thompson Medicines Management Adviser Greater Glasgow Primary Care Trust. Ppis are used for the treatment of gastro intestinal acid secretary disorders study area the present market research of ppis was carried out in five different hospitals bombay hospital, bhandari hospital, gokuldas hospital, shakuntal hospital & bafana hospital ; and fifteen chemists rohan chemist, mantri medicose, mehta chemist, manohar brothers, mahaveer medicose, agarwal chemist, meera medicose, piyush chemist, new citizen chemist, maya medicose, laxmi chemist, pooja medical store, subham, sneh & saif medicose ; , located in different areas of indore, study sites were selected considering the number of patient in the hospital, prescription and sale of ppis at the chemists and monopril.
Weight change was recognized as a feature of schizophrenia even before antipsychotic drugs were introduced in the 1950s . Schizophrenia--independent of drug treatment--also is a risk factor for the development of type 2 diabetes Is it possible that schizophrenic patients are "primed" or more sensitive to the weight gain potential from these drugs?.
Anaphylactic Reaction 8 Unconscious Patient 8 CARDIAC 9 TRAUMA 12 Table of Suspicion 20 21.
1. Given cyclically for short term use only: For treatment of moderate to severe vasomotor symptoms, or moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. Administration should be cyclic e.g., 3 weeks on and 1 week off ; . USUAL DOSAGE RANGES: Vasomotor symptoms 1.25 mg daily. If the patient has not menstruated within the last 2 months or more, cyclic administration is started arbitrarily. If the patient is menstruating, cyclic administration is started on day 5 of bleeding. Moderate to severe symptoms of vulvar and vaginal atrophy 0.3 mg to 1.25 mg or more daily, depending upon the tissue response of the individual patient. Administer cyclically. 2. Given cyclically: Female hypogonadism; female castration; primary ovarian failure. USUAL DOSAGE RANGES: Female hypogonadism 2.5 to 7.5 mg daily, in divided doses for 20 days, followed by a rest period of 10 days' duration. If bleeding does not occur by the end of this period, the same dosage schedule is repeated. The number of courses of estrogen therapy necessary to produce bleeding may vary depending on responsiveness of the endometrium. If bleeding occurs before the end of the 10 day period, begin a 20 day estrogen-progestin cyclic regimen with Menest esterified estrogens tablets ; , 2.5 to 7.5 mg daily in divided doses, for 20 days. During the last 5 days of estrogen therapy, give an oral progestin. If bleeding occurs before this regimen is concluded, therapy is discontinued and may be resumed on the fifth day of bleeding. Female castration and primary ovarian failure -- 1.25 mg daily, cyclically. Adjust dosage upward or downward according to severity of symptoms and response of the patient. For maintenance, adjust dosage to lowest level that will provide effective control. 3. Given chronically: Inoperable progressing prostatic cancer -- 1.25 to 2.5 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient. Inoperable progressing breast cancer in appropriately selected men and postmenopausal women. See INDICATIONS AND USAGE ; Suggested dosage is 10 mg three times daily for a period of at least 3 months. Treated patients with an intact uterus should be monitored closely for signs of endometrial cancer and appropriate diagnostic measures should be taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding. The lowest effective dose of Menest has not been determined. HOW SUPPLIED Tablets: 0.3 mg yellow, film-coated oblong tablet imprinted with M72 100's: NDC 61570-072-01 0.625 mg orange, film-coated oblong tablet imprinted with M73 100's: NDC 61570-073-01 500's: NDC 61570-073-05 1.25 mg green, film-coated oblong tablet imprinted with M74 100's: NDC 61570-074-01 2.5 mg pink, film-coated oblong tablet imprinted with M75 50's: NDC 61570-075-50. Use of identical images to illustrate east african and west african trypanosomes is unacceptable, for example, what is lotrel used for. Walsh JK, et al. In: Kryger MH, et al, eds. Principles and Practice of Sleep Medicine. 4th ed. 2005: 749-760 and lysergic. Diovan Lamisil Tablets Otrel . Zemuron.
5. Legal proceedings update A number of our affiliates are the subject of legal proceedings arising out of the normal conduct of their business. As a result, claims could be made against them which, in whole or in part, might not be covered by insurance. In our opinion, however, the outcome of these actions will not materially affect our financial condition but could be material to our results of operations in a given period. Significant recent developments are as follows: Chiron Proposed Acquisition: On April 3, Chiron announced it had reached an agreement in principle to settle all claims in the previously reported stockholder actions challenging the proposed transaction with Novartis. The proposed settlement is subject to court approval following notice to the class and a hearing. Contact Lenses: In late 2005, CIBA Vision was served with a complaint by Rembrandt Vision Technologies alleging infringement of US Patent No. 5, 712, 327. While no products are specifically named in the lawsuit, it is expected that the plaintiffs will allege infringement by CIBA Vision's FOCUS Night & Day and or O2OPTIX contact lenses. In addition, in April 2006, CooperVision filed a suit against CIBA Vision in the US seeking a declaration that the upcoming launch of their Biofinity product does not infringe patents protecting CIBA Vision's products the "Nicolson" patents ; and or that the patents are invalid. CooperVision also filed suit in a separate court alleging CIBA Vision's O2OPTIX lenses infringe two sets of patents, one relating to features that control edge characteristics of certain types of contact lenses and the other relating to designs for certain types of contact lenses, including one that helps treat astigmatism. Gender Discrimination: Certain US Novartis affiliates are defendants in a purported class action brought in the Federal Court in New York by certain female pharmaceutical sales representatives who allege that they were discriminated against because of their gender. This case is in discovery. The Novartis affiliates intend to vigorously defend themselves in this matter. Lktrel Cibacen Lotensin Cibadrex: In addition to Teva, Watson Pharmaceuticals has also sought marketing approval for the same benazepril combination product as Lotrel, and is thus seeking to bring a fully substitutable product to the US market. Novartis has filed suit against Watson in the US for patent infringement. PPA: As of March 31, 2006, a total of approximately 21 lawsuits remained pending against Novartis affiliates in the US down from 52 at December 31, 2005 ; brought by people claiming to have been injured by products containing phenylpropanolamine PPA ; sold by certain of those affiliates. Trial dates have been scheduled over the next 12 months for 11 cases. There can be no guarantee that our initial successes in defending these claims will be repeated or sustained. Wage and Hour Litigation: Counsel for certain pharmaceutical sales repre-sentatives have filed suit in the State Courts in California and New Jersey and in the Federal Court in New York against Novartis affiliates alleging the affiliates violated wage and hour laws by failing to pay overtime pay to the sales representatives. Certain claims are brought on behalf of a purported class of plaintiffs. The Novartis affiliates intend to vigorously defend themselves.
Lotrel cap as it is known, it lotrel cap contains 5 mg5 mg of the emedtv resource designed to lotrel cap improve wellbeing.
Scriptions cited in the traditional texts do not contain those details which are necessary for the scientific identification of the plant species. The identity of medicinal plants collected at present may differ from those plants referred to in traditional texts. This may be due to other collecting regions in the past, to the existence of numerous synonyms and local names and to different local traditions that Tibetan doctors follow. Until now scientific publications on Tibetan plant drugs are rare, at least in the West. Besides, no modern pharmacopoeia of Tibetan medicine, which could provide guidelines for checking Tibetan drugs, exists. However, in an earlier interdisciplinary project on Tibetan medicinal plants the author contributed to the research of Tibetan plants by giving particulars for the examination of 100 selected plants vide Ch. Kletter, M. Kriechbaum [2001], Tibetan Medicinal Plants, medpharm Scientific Publishers, Stuttgart; CRC Press, Boca Raton, London, New York, Washington, D.C. ; . The first edition of a Tibetan pharmacopoeia should include a selection of the most frequently used Tibetan plant drugs, especially those which may be found in preparations distributed in the West. Such a pharmacopoeia should contain monographs headed by a Tibetan plant name, define the botanical identity of each drug-furnishing plant, include microscopic descriptions of the used plant part s ; , refer to other plants which my be traded under a specific Tibetan name, comment on the plant's use in Tibetan medicine and inform about its toxicity. The first step in achieving this goal is establishing an interdisciplinary and intercultural network of skilled persons and institutions who are willing to participate in such an ambitious undertaking. ondrashov, N. Kondrashov, Alexej N. MNG Manuscripts on Mongolian Traditional Medicine The study of Mongolian traditional medicine manuscripts provides access to a rich medical heritage of nomadic tribes of Central Asia. Medical manuscripts contain valuable information about medicines and raw materials used in traditional medicine. Most of them have been written in old Mongolian and Tibetan languages. The paper provides detailed information about authors and manuscripts of Mongolian traditional medicine. Mongolian medicine has accumulated the rich tradition of Tibetan medicine which came to Mongolia via Buddhism in 14th-17th centuries. Since that period major Tibetan medical manuscripts became popular among Mongolian doctors, some of them have been translated into Mongolian language. The first school of Tibetan medicine was opened in Mongolia in 1685 by Luvsandanzan 1636-1704 ; , famous Mongolian doctor. He wrote many valuable manuscripts which are important even now: Teaching about different diseases" Nad zhi dvi vi rnam vshad ; , Recipe Collections Man rag vdu za seg szhor ; etc. There is a growing tendency in a many countries to combine modern Western Diagnostic and Treatment methods with traditional medicine. Mongolian medicine is no exception, however very little material has been translated so far. The history of Mongolian traditional medicine is not studied very much.